Figure 1: In the coating process, each tablet receives numerous partial coatings, which leads to a homogeneous coating layer.
The scanning electron microscopy (SEM) picture shows a cross-section of the coating layer on the tablet core. (ALL FIGURES
COURTESY OF THE AUTHORS)
Drum coaters are widely used in the pharmaceutical industry to produce film-coated tablets. The coating layer(s) around the
tablet core can serve many purposes, such as tastemasking, coloring, control of the release of the API from the core of a
tablet, application of an additional API, or protection of the tablet core from environmental influences. In this process,
an atomizing nozzle above the tablets sprays the coating solution onto the tablets, which are mixed by the rotating drum.
Heated air is forced through the system to enhance drying of the coating. In this way, each tablet receives a series of partial
coatings (see Figure 1). A crucial issue is coating uniformity, which includes both inter-tablet uniformity (i.e., variation of coating mass from
one tablet to the other) and intra-tablet uniformity (i.e., variation of the coating thickness and quality on the surface
of a single tablet) (1–3). Inhomogeneity in coating thickness, for example, could lead to significant variations in API content
or delivery rate. In many cases, a single tablet that fails testing can lead to rejection of the whole batch.
CHRIS ROGERS/GETTY IMAGES
Parameters that influence drum-coating performance can be divided into two groups. The first group includes parameters that
can be adjusted by the operator (e.g., drum-rotation speed, fill level, spraying rate, or drying-air temperature). The second
group are parameters that cannot be adjusted directly, but have a direct influence on the quality of the product (e.g., extension
of the spray zone, mixing efficiency, air flow pattern, and quality of the coating spray) (4).
Although drum coating is commonly used in the pharmaceutical industry, there have been relatively few scientific investigations
reported in the literature. Moreover, process design has been based mostly on trial-and-error and operator experience. Recently,
in addition to experimental work, advances in computational simulations have become an important tool for such investigations
Figure 2: A schematic representation shows different process regimes of the coating process with an appropriate simulation
approach used for each. For (a) and (c), colors denote velocity from slow (blue) to fast (red). In (b), the red color represents
coating thickness; the tablet on the right in the lower box has a thicker coating.
The major objective of this work is to show how a combination of different numerical techniques can help to provide a comprehensive,
in-silico (i.e., via computer simulation) analysis of the whole tablet-coating process. The following aspects of the film-coating process
aspects were identified (see Figure 2):
Simulation of the tablet bed mixing using the discrete element method (DEM)
Detailed numerical analysis of the interaction between spray droplets and the tablet surface by means of advanced multiphase
computational fluid dynamics (CFD) methods
Computational analysis of the coater internal flow in terms of drying air, spray, and wall effects using CFD.
The work aims to provide a deeper understanding of:
The tablet-mixing process in an industrial pan coater, which allows optimization of the tablet residence time in the spray
The local behavior of the spray droplets impacting on a single tablet, which leads to a wider understanding of film formation
The interaction between the spray and coater drying air, thus allowing a detailed analysis of the deposition efficiency of
coating material on the tablet bed and insight into operative problems like overspray, filter plugging, or incomplete tablet-coat
Johannes G. Khinast is a professor at the Graz University in Austria and Head of the Institute of Process and Particle Engineering
Scientific Director Research Center Pharmaceutical Engineering (RCPE).
Articles by Johannes G. Khinast
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.